TABLE 2

Characteristics of patients who received antifibrotic treatment and those who did not

Patients with >6months treatmentPatients without treatment or <6months treatmentDifference between groups
p-value
Patients95358
Age at diagnosis years67.4±7.874.5±8.8<0.0001
Sex0.003
 Male74 (77.9%)221 (61.7%)
 Female21 (22.1%)137 (38.3%)
BMI kg·m−229.0±5.328.2±5.10.207
Smoking0.015
 Never smoker31 (33.3%)166 (48.1%)
 Ex-smoker57 (61.3%)153 (44.4%)
 Current smoker5 (5.4%)26 (7.5%)
DLCO % predicted53.2±14.156.5±16.90.111
FVC L2.8±0.72.7±0.90.338
FVC % predicted72.4±13.682.4±18.7<0.0001
GAP stage0.006
 GAP 133 (40.2%)167 (58.0%)
 GAP 246 (56.1%)105 (36.5%)
 GAP 33 (3.7%)16 (5.6%)
Transplantation7 (7.3%)6 (1.7%)
Deaths25 (26.3%)154 (43.0%)
IPF-related deaths21 (84.0%)93 (60.8%)

Data are presented as mean±sd unless otherwise stated. BMI: body mass index; DLCO: diffusing capacity of the lung for carbon monoxide; FVC: forced vital capacity; IPF: idiopathic pulmonary fibrosis. Bold indicates statistically significant p-values.